IL-22BP/IL22 RA2 Antibody

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Interleukin 22 binding protein (IL-22BP), also known as cytokine receptor family (CRF) 2‑10, CRF2-X, and IL-22 RA2, is a secreted glycoprotein belonging to the type II cytokine receptor family. The IL-22BP gene has been localized to chromosome 6 near the gene for IFN-gamma R1. It encodes a precursor protein of 231 amino acid (aa) residues with a 21 aa putative signal peptide and five potential N-linked glycolsylation sites. IL-22BP lacks a transmembrane and cytoplasmic domain and is most closely related to the extracellular domains of IL‑22 R (CRF2-9) and IL-20 R (CRF2-8), sharing 33% and 34% aa sequence identity, respectively. It also shares sequence homology with the extracellular domains of IL-10 R (29%), IL-10 R beta (30%), the IFN receptors (23‑25%) and tissue factor (26%). IL-22BP antagonizes IL-22 activity by specifically binding IL-22 with high affinity and blocking its interaction with the cell surface IL-22 receptor heteromeric complex composed IL‑22 R and IL‑20 R. IL‑22BP is expressed in multiple tissues. The highest levels of expression are found in breast, lungs and colon.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: ELISA Development (Capture), Neutralization.

Showing Publications 1 - 6 of 6.

Publications using AF1087	Applications	Species
P Gómez-Fern, A Lopez de L, I Astobiza, J Mena, A Urtasun, V Altmann, F Matesanz, D Otaegui, E Urcelay, A Antigüedad, S Malhotra, X Montalban, T Castillo-T, L Espino-Pai, O Aktas, M Buttmann, A Chan, B Fontaine, PA Gourraud, M Hecker, S Hoffjan, C Kubisch, T Kümpfel, F Luessi, UK Zettl, F Zipp, I Alloza, M Comabella, CM Lill, K Vandenbroe The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis Cells, 2020-01-10;9(1):. 1/10/2020 [PMID: 31936765]
Paloma Gómez-Fernández, Andoni Urtasun, Ianire Astobiza, Jorge Mena, Iraide Alloza, Koen Vandenbroeck Pharmacological Targeting of the ER-Resident Chaperones GRP94 or Cyclophilin B Induces Secretion of IL-22 Binding Protein Isoform-1 (IL-22BPi1) International Journal of Molecular Sciences 2019-05-17 [PMID: 31108847]
Paloma Gómez-Fernández, Andoni Urtasun, Adrienne W. Paton, James C. Paton, Francisco Borrego, Devin Dersh et al. Long Interleukin-22 Binding Protein Isoform-1 Is an Intracellular Activator of the Unfolded Protein Response Frontiers in Immunology 2018-12-14 [PMID: 30619294]
Shi Bin Yang, Fanghai Han, Jian Hai Wu, Zhi Zhao, Wenhua Zhan Association between CXCR2 and IL-22BP expression indicate a poor outcome for gastric adenocarcinoma progression Oncology Letters 2016-08-01 [PMID: 27446456]
Perriard G, Mathias A, Enz L, Canales M, Schluep M, Gentner M, Schaeren-Wiemers N, Du Pasquier R Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. J Neuroinflammation, 2015-06-16;12(0):119. 2015-06-16 [PMID: 26077779] (ELISA Development (Capture), Human)	ELISA Development (Capture)	Human
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R IL-22 increases the innate immunity of tissues. Immunity, 2004-08-01;21(2):241-54. 2004-08-01 [PMID: 15308104] (Neutralization, Human)	Neutralization	Human

Array AF1087

• IL-22BP/IL22 RA2 Antibodies
• IL-22BP/IL22 RA2 Antibody Pair
• IL-22BP/IL22 RA2 Lysate
• IL-22BP/IL22 RA2 Protein
• IL-22BP/IL22 RA2 ELISA
• IL-22BP/IL22 RA2 Proteins and Enzymes